GlassScriptPhysician profile
Bruce Anthony Fine
NPI 1982646121
$4,033.42
in general payments reported to CMS, 2019-2025
15 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.11 · 2020: $1,210 · 2021: $425 · 2022: $527 · 2023: $252 · 2024: $758 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $19.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.87 |
| Education | $19.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $1,003.18 | 2024-2025 | Hemoblast Bellows |
| Intuitive Surgical, INC. | $935.40 | 2020 | |
| Myriad Genetic Laboratories, INC. | $602.13 | 2022-2025 | Precisetumor, Myrisk |
| Biom'Up France Sas | $426.92 | 2020-2021 | |
| Stryker Corporation | $223.45 | 2021-2022 | |
| Ethicon US, LLC | $177.54 | 2025 | Stratafix, Vistaseal, Evarrest |
| Caris Mpi, INC. | $152.21 | 2025 | Mi Cancer Seek |
| Davol INC. | $114.00 | 2022 | |
| Glaxosmithkline, LLC. | $106.15 | 2020 | |
| Tempus Ai, INC | $99.56 | 2024 | Xt Cdx |
| Becton, Dickinson and Company | $93.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.85 | 2023 | |
| Genmab U.S., INC. | $19.77 | 2025 | Tivdak |
| Beigene USA, INC. | $16.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.